New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver ...

ORIC Pharmaceuticals (ORIC) lost ~22% in extended trading after the company reported data from a Phase 1b trial for its ...

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...

Patches that lower testosterone by delivering oestradiol, a form of oestrogen, through the skin were just as effective as injections at preventing the cancer from spreading ...

Women’s HRT patches control prostate cancer as well as standard hormone injections, but with fewer hot flushes and less bone ...

The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

Based on the efficacy and safety data, Oric will advance the 400mg therapy to Phase III trials, with more treatment-emergent ...

A randomized study in 58 men with limited metastatic prostate cancer found that PSMA therapy postponed the need for hormone ...

Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...

A recent study published in The New England Journal of Medicine found that transdermal estradiol (tE2) therapy was ...